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Aims The role of chest computed tomography (CT) is not well defined for either diagnosis or management of pericardial
disease. The aim of this study was to evaluate the added value of early chest CT in the diagnostic workup for patients
presenting with cardiac tamponade or large pericardial effusion of unknown aetiology as the first manifestation of
disease.
Methods
and results
We performed CT scan on 55 patients with pericardial effusion as defined above, undergoing echo-guided pericardio-
centesis. We compared the success rate in making diagnosis and/or staging the underlying disorder of three sequential
workups, including, respectively, (i) clinical presentation, inflammatory markers, chest X-ray imaging, (ii) all of the above
and pericardial fluid analysis, and (iii) all of the above and chest CT.Wewere able tomake diagnosis in 53 patients (96%):
the major cause of effusion was malignancy (38%). Clinical and biochemical data were not able to differentiate non-tu-
mour from tumour patients. CT revealed pathological findings in all patients with malignancy: tumour mass in 15/21
(71%) and pathological lymphadenopathy in the remaining 6 cases. The workup including CT provided a significantly
higher diagnostic yield than the other two workups (P, 0.0001), both in the overall population and in the two sub-
groups of neoplastic (Npl) and non-Npl patients.
Conclusion In all patients with cardiac tamponade or large pericardial effusion, CT was useful either in identifying the underlying
disease or in excluding other potential causes of pericardial effusion. We conclude that chest CT is a very useful non-
invasive diagnostic tool to identify and stage pericardial diseases.
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Introduction
Pericardial effusion may be caused by many disorders, such as infec-
tious diseases, cancer, autoimmune, and metabolic diseases.1–4 The
underlying pathology is often known, but the diagnosis could be
challenging for those patients who present with a pericardial effu-
sion as the first sign of disease.5,6 Clinical series of patients with large
pericardial effusion have reported a low rate of idiopathic causes;
conversely, a neoplastic (Npl) aetiology has been repeatedly and
consistently reported and is associated with a poor prognosis.7–10
An early diagnosis and treatment may favourably impact on the out-
come of these patients.11
Among the imaging techniques used for diagnosis, echocardiog-
raphy remains the cornerstone for its ease of execution and for
* Corresponding author. Tel: +39 0395916422; Fax +39 039591647. E-mail: maggiolinistefano@yahoo.it
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2015. For permissions please email: journals.permissions@oup.com.
European Heart Journal – Cardiovascular Imaging (2016) 17, 421–428
doi:10.1093/ehjci/jev225
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcim
aging/article-abstract/17/4/421/2464813 by U
niverità degli Studi di M
ilano user on 12 February 2019
its ability to assess the haemodynamic aspects of the effusion.
Nevertheless, its diagnostic capability to recognize the underlying
aetiology is low.12
In these patients, chest computed tomography (CT) can offer
some advantages: this imaging technique allows assessment of the
entire chest and detection of associated abnormalities in the medi-
astinum, lung, and adjacent structures.12,13 The guidelines of the
European Society of Cardiology for the diagnosis and management
of pericardial diseases consider chest CT as an optional diagnostic
tool that is indicated only when previous test results have been
inconclusive.2
The aim of the present study is to evaluate the incremental value
of chest CT in the aetiological investigations of patients with cardiac
tamponade or large pericardial effusion as the first manifestation of
the disease.
Methods
We had prospectively collected data from 123 consecutive patients, ac-
cording to a predefined protocol, who underwent 141 echo-guided
pericardiocentesis between 1993 and 2013: of these, 55 were included
in this study based on the criteria depicted in Figure 1.
The indication for the pericardiocentesis was the presence of large
pericardial effusion or cardiac tamponade. The effusion was classified
as large if the sum of anterior and posterior echo-free spaces was major
than 20 mm at end-diastole.14 The diagnosis of cardiac tamponade was
made with clinical parameters (tachycardia, dyspnoea, hypotension, and
paradoxical pulse) and echocardiographic parameters (right ventricular
diastolic collapse, right atrial collapse, and an inspiratory decrease in
mitral E-wave velocity of 25% or more).15–18
Echo-guided pericardiocentesis was performed in the coronary care
unit, using the bidimensional echocardiography to detect the position
and amount of pericardial effusion. The percutaneous puncture was car-
ried out in the site where the pericardial space was closest to the probe
and where the largest amount of fluid was detected. The needle was ad-
vanced through the tissues and inside the pericardial space under con-
tinuous visualization according to the technique previously described.19
The 55 patients included in this study underwent the aetiological
investigations recommended by the European Guidelines for the man-
agement of pericardial diseases and contrast-enhanced chest CT.
Routine blood tests were performed, including C-reactive protein
(CRP) and/or ‘erythrocyte sedimentation rate’ (ESR), LDH, and differ-
ential WBC. The pericardial fluid was tested for protein, LDH, and
cholesterol levels; aerobic and anaerobic cultures; cytology; and culture
and polymerase chain reaction to identify Mycobacterium tuberculosis.
Other blood or instrumental tests were performed according to clinical
conditions (such as anti-nuclear antibodies, thyroid function, liver func-
tion, etc.), if first-level tests were negative.
The diagnosis of viral or idiopathic acute pericarditis was assigned
when the patient had a recent history of infection, elevation of inflam-
matory markers and clinical signs as typical chest pain, ECG modifica-
tions, self-limiting course of the disease, and when other causal
factors could be excluded.20 The diagnosis of chronic idiopathic pericar-
dial effusion was made when the liquid persisted for at least 3 months
without evidence of a specific cause. Effusion secondary to heart failure,
end-stage renal disease, cirrhosis, and rheumatologic disease or asso-
ciated with oral anticoagulant (OAC) therapy was diagnosed when
these conditions were present in the absence of other specific causes.5
For each patient, we then compared the potential yield of three dif-
ferent workups to reach the final diagnosis/staging of the disease. The
first workup included clinical presentation (fever, dyspnoea, chest
pain, heart rate, and blood pressure), inflammatory markers (CRP,
ESR, and WBC), and chest X-ray imaging (workup 1 ¼ w1); the second
included clinical presentation, inflammatory markers, chest X-ray, and
pericardial fluid analysis (workup 2 ¼ w2); finally, the third included all
of the above analyses and contrast-enhanced chest CT scan (workup
3 ¼ w3).
All patients gave permission for use of their clinical data for research
purposes.
Statistical analysis
Continuous data are reported as mean+ SD and compared with two-
tailed unpaired Student’s t-test. Categorical variables are expressed as
percentages and compared with the Fisher’s exact test. The Cochran’s
Q test was used to compare the distributions of the two dichotomous
outcomes (failure or success in diagnosing and/or staging the underlying
disease) across the three workups, i.e. to analyse the success rate of the
workups, followed by a post hoc comparison to assess which of the pro-
portions are significantly different from which other proportions. A
P-value of ,0.05 was considered statistically significant.
Results
Fifty-five consecutive patients with pericardial effusion and/or car-
diac tamponade of unknown aetiology at the presentation were
identified. Patients’ characteristics are reported in Table 1.
At the end of the aetiological investigation, we were able to make
a final diagnosis in 53 of 55 patients (96%, Table 2), i.e. malignancy in
21 patients (38%), acute viral/idiopathic pericarditis in 10 cases
(18%), bronchopneumonia in 6 cases (11%), associated with OAC
therapy in 5 cases, tuberculosis in 4 patients (7%), autoimmune
Figure 1 Flow chart of patient enrolment and selection criteria
for the study.
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disease in 2 patients (3.6%), uraemia in 2 patients (3.6%), as well as
cholesterol pericarditis, anasarca in cirrhosis, and heart failure in 1
case each (1.8%). In the remaining two cases, the aetiological diag-
nosis remained unidentified. All diagnoses were confirmed at
6-month follow-up.
Comparison between Npl and non-Npl (NNpl) patients showed
that clinical data (fever, dyspnoea, and chest pain) and biochemistry
were similar, whereas mean age was significantly lower in Npl pa-
tients (Table 1, on the right). Chest radiography showed a parenchy-
mal consolidation in 10 Npl patients, whereas in the NNpl group a
pathological consolidation was found at the initial observation in 3 of
6 patients with pneumonia.
The volume of the pericardial fluid drained did not differ between
the two groups. Excluding the 5 patients on warfarin, who belonged
to the NNpl group in our series, bloody effusion was found in 14 of
21 Npl (66.7%) vs. only 9 of 28 NNpl patients (32.1%; P ¼ 0.022).
However, overall the sensitivity and specificity of bloody effusion
to predict malignant pericardial disease were 66.7 and 58.8%,
respectively. A positive result for cytological examination of the
pericardial fluid was obtained in 11 of the 21 Npl patients
(52.4%). In spite of its obvious very high specificity, the sensitivity
of malignant pericardial effusion in predicting malignant disease
was 52.4%.
Chest CT showed pathological findings in 29 of the 55 patients
(52.7%), namely in all Npl patients and in 8 of the 34 NNpl patients
(Table 3). A chest CT scan directly showed the tumour mass in 15 of
21 Npl patients (71%) and in the remaining 6 cases (29%) revealed
pathological lymphadenopathy alone, defined as lymph nodes larger
than 1 cm (Figure 2).21–24 In patients with non-thoracic neoplasms
(gastric, kidney, or genital cancer), a CT scan showed the renal
mass or enlarged lymph nodes. Even in the case of tumour of
unknown origin, CT revealed pathological lymphadenopathy.
Detection of pathological adenopathies occurred in 13 of the 21
Npl patients (62%), but only in 3 of the 34 NNpl subjects (9%;
P, 0.001): of these latter, one patient was affected by pneumonia
associated with HIV, one by cholesterol pericarditis, and one by
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Table 1 Baseline patient characteristics
Cohort Npl group NNpl group P-value
Patients, n (%) 55 21 (38.0) 34 (62.0)
Sex, n (%)
Male 34 (61.8) 14 (66.6) 20 (58.8) 0.776
Female 21 (38.2) 7 (33.4) 14 (41.2)
Age (years)
Mean+ SD (range) 62.2+18.1 (16–92) 55.7+18.0 (16–79) 66.2+17.1 (32–92) 0.034
Clinical data, n (%)
Fever 26 (47.3) 7 (33.4) 19 (55.8) 0.164
Dyspnoea 38 (69.1) 13 (61.9) 25 (73.5) 0.386
Chest pain 18 (32.7) 5 (23.8) 13 (38.2) 0.377
Tamponade 41 (74.5) 17 (80.9) 24 (70.5) 0.529
Biochemistry, n (%)
Elevated CRP/ESR 46 (83.6) 17 (80.9) 29 (85.2) 0.719
Blood tumour markers 13 (23.6) 13 (61.9) 0 ,0.0001
ECG, n (%)
ST elevation 12 (21.8) 4 (19.0) 8 (23.5) 0.750
Low amplitude QRS 19 (34.5) 9 (42.8) 10 (29.4) 0.386
Chest X-ray, n (%)
Pleural effusion 34 (61.8) 14 (66.7) 20 (58.8) 0.776
Parenchymal lung lesion 13 (23.6) 10 (47.6) 8 (23.5) 0.081
Pericardial fluid drained (mL)
Mean+ SD (range) 862+450 (120–2000) 886+488 824+392 0.626
Effusion’s characteristics, n (%)
Bloody 28 (50.9) 14 (66.7) 14 (41.2) 0.097
Serous 13 (23.6) 3 (14.3) 10 (29.4) 0.328
Serosanguineous 12 (21.8) 4 (19.0) 8 (23.5) 0.529
Purulent 1 (1.8) 0 1 (0.3) 1
Malignant cells in pericardial fluid, n (%) 11 (20.0) 11 (52.4) 0 ,0.0001
Fluid LDH (UI/L)
Mean+ SD 923+834 1008+920 871+793 0.634
Npl, neoplastic; NNpl, non-neoplastic; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
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tuberculosis. In all the four cancer cases with negative cytology and
no bloody effusion, chest CT showed pathological findings: a medi-
astinal mass in the two patients with lymphoma, pathological lymph
nodes in a patient with gastric cancer, and the renal mass in the case
of kidney cancer. In patients without malignancy (Figure 3), chest CT
demonstrated parenchymal lesions in all cases of pleuropericarditis
associated with pneumonia and with non-diagnostic chest X-ray
(three patients), and revealed pulmonary calcifications in two of
the four patients with tuberculosis. Furthermore (Figure 3), chest
CT excluded the presence of a tumour in all patients with bloody
effusion either on OAC therapy or with acute pericarditis (five
and four subjects, respectively) and in three patients with acute vir-
al/idiopathic pericarditis without the classic presentation of a triad of
fever, chest pain, and elevated inflammatory markers. Overall, the
sensitivity and specificity of the presence of pathological nodules
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Aetiology of pericardial effusion
Aetiology n (%)
Malignancy 21 (38.0)
Lung cancer 12
Lymphoma 3
Gastric adenocarcinoma 2
Cardiac sarcoma 1
Kidney cancer 1
Genital cancer 1
Metastatic primary tumour unidentified 1
Acute viral/idiopathic pericarditis 10 (18.0)
Associated with pneumonia 6 (11.0)
Associated with OAC therapy 5 (9.0)
Tuberculosis 4 (7.0)
Rheumatological disease 2 (3.6)
Uraemia 2 (3.6)
Heart failure 1 (1.8)
Cirrhosis 1 (1.8)
Cholesterol pericarditis 1 (1.8)
Chronic idiopathic 2 (3.6)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Chest CT results
Chest CT NNpl Npl P-value
Number of patients 34 21
Parenchymal lesions, n (%) 8 (23.5) 15 (71.4) 0.0007
Specific for pneumonia, n (%) 6 (17.6)
Specific for tuberculosis, n (%) 2 (5.9)
Pathological lymph nodes, n (%) 3 (8.0) 13 (61.9) ,0.0001
Calcified, strongly suspicious of tuberculosis, n (%) 1 (2.9)
Aspecifica, n (%) 2 (5.9)
Negative, n (%) 26 (76.5) 0 (0) ,0.0001
Npl, neoplastic; NNpl, non-neoplastic.
aOne associated with pneumonia in HIV infection, and one associated with cholesterol pericarditis.
Figure 2 Representative chest CT scans with contrast enhance-
ment, mediastinal window. (A) Lung cancer (white arrow), pericar-
dial and pleural effusion. (B) Pathological mediastinal lymph node
(white arrow).
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and/or lymphadenopathies detected by chest CT in diagnosing ma-
lignant disease were 100 and 91.2%, respectively.
Finally, we compared the performance of the three different diag-
nostic workups described in the methods to reach a final diagnosis
and/or definitive staging of the underlying disorder. As shown in
Figure 4A, the yield of the workup that included CT scan (w3) was
significantly higher when compared with w1 and w2, which did
not include CT scan (69.1, 10.9, and 25.5%, respectively). This was
true also when we divided the total sample in the two subgroups of
NNpl and Npl patients and compared the performance of the three
workups within the two groups (Figure 4B): again, the workup in-
cluding CT (w3) proved to be significantly better than w1 and w2,
both in the NNpl (50, 8.8, and 17.7%, respectively) and in the Npl
group (100, 14.3, and 38.1%, respectively).
In eight patients, no workup was able to reach the final diagnosis
(patients with cirrhosis, heart failure, uraemia, rheumatologic dis-
ease, or chronic idiopathic pericardial effusion) and further investi-
gations were necessary. Still, chest CT was useful to exclude an
occult neoplasm.
Discussion
The major finding of the present study was that for patients with
cardiac tamponade or large pericardial effusion at presentation,
Figure 3 Chart showing the value of early chest CT scan in the diagnostic workup of patients presenting with cardiac tamponade or large peri-
cardial effusion of unknown aetiology. Black boxes and bold text highlight cases with (on the left) or without (on the right) signs of malignancy, for
which chest CT was essential in obtaining the final diagnosis. In patients with non-malignant conditions, chest CT (i) demonstrated inflammatory
consolidations diagnostic for pneumonia undetectable to chest X-ray, (ii) showed pulmonary calcifications typical of tuberculosis, and (iii) ruled
out the presence of a tumour in cases with bloody effusion or without fever and/or elevation in inflammatory markers. Grey boxes and italic text
point out cases in which early chest CTwas useful but not conclusive for differential diagnosis. In these cases, chest CT (i) confirmed inflammatory
lung infiltrates in pneumonia detected by chest X-ray or (ii) excluded occult neoplasms.
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the aetiology can be identified in most cases with a correct
workup including early chest CT scan. In fact, only 3.6% of the
effusions remained unclassified in our series. Malignancy was
found in 38% of the patients and was the most common cause
of pericardial disease. Similar observations are reported in other
clinical series: Kabukcu et al.25 and Cornily et al.26 showed that
cancer diseases were the most frequent cause of cardiac tam-
ponade (30 and 65%, respectively). In our study, lung cancer
was the predominant cause of malignant pericarditis, similar to
other reports.27 – 29
Among the parameters usually employed in the diagnostic path-
way, inflammatory markers and the amount of pericardial fluid were
not able to differentiate patients with cancer, whereas the presence
of bloody effusion was significantly higher in the group with malig-
nant disease but with a limited sensitivity and specificity. The identi-
fication of malignant cells in the liquid was highly specific for cancer,
but the sensitivity was rather low (52%). Similar data have been re-
ported in the studies of Tsang et al.,28 Pawlak Cieslik et al.,29 and
Maisch et al.30 The use of invasive techniques, such as pericardial
biopsy (not available in all centres), improves the diagnostic sensitiv-
ity, ranging from 24 to 85%, depending on the number of biopsies
and the technique.2,30 This procedure remains investigational and
it is warranted only in skilled tertiary referral centres for selected
cases, when a specific disorder is suspected and cannot be diag-
nosed by traditional diagnostic means.6 The addition of chest CT,
an easily available, non-invasive test, allowed making an aetiological
diagnosis in 96% of our patients.
In the Npl group, chest CT revealed pathological findings in 100%
of cases by direct visualization of the tumour (71%) and/or enlarged
mediastinal lymph nodes (62%). No patient with malignancy had
negative CT scan findings. The occurrence of pathological lympha-
denopathies in patients with large pericardial effusion is an import-
ant marker of Npl disease, as documented by Sun et al.31 and Pawlak
Cieslik et al.29 Sun et al. reported enlarged mediastinal lymph nodes
in 60.7% of patients with malignancy and in 6.5% of patients without
cancer, whereas Pawlak Cieslik et al. reported pathological findings
in 90% of cancer vs. 29% of non-cancer patients. Notably, no pa-
tients with viral/idiopathic pericarditis had pathological lymphaden-
opathy (.1 cm) in our series.
Even in patients with negative cytology and non-haemorrhagic
effusion, in which the probability of malignancy was low, chest
CT allowed a definitive diagnosis, without further delay or use of
invasive tests. Furthermore, in all patients with non-thoracic neo-
plasia, a CT scan detected abnormal findings: pathological lymph
nodes in patients with gastric cancer, genital neoplasia, and cancer
of unknown origin and a renal mass, being it adjacent to the dia-
phragm. These latter observations are important, because chest
CT offers a clue to uncover non-lung Npl aetiology of the pericar-
dial effusion.
In patients without cancer (Figure 3), early chest CT was essential
for the aetiological diagnosis of pneumonia in cases without diagnos-
tic X-ray (50% of the patients with this condition) and of pulmonary
tuberculosis in cases with suspicious calcifications (50% of the sub-
jects with this specific infectious disease). In addition, chest CT ruled
out an Npl aetiology in 70% of patients with acute pericarditis (pre-
senting either with bloody effusion or without the triad of elevated
inflammatory markers, fever, and chest pain) and in 100% of patients
onOAC therapy (all with bloody effusion). For patients with chronic
Figure 4 Yield of three workups in reaching final diagnosis/staging in patients presenting with cardiac tamponade or large pericardial effusion of
unknown aetiology. Workup 1 included clinical presentation, inflammatory markers, and chest X-ray imaging; workup 2 included all of the above
and pericardial fluid analysis; in workup 3, we added contrast-enhanced chest CT to workup 2. (A) Comparison of the performance of the three
workups in the whole patient cohort. Significance of the Cochran’s Q test: P ¼ 9.6 × 1029. (B) Comparison of the success rate of the three work-
ups within the two subgroups of patients with or without malignancy. Significance of the Cochran’sQ test: P ¼ 4.4 × 1026 and P ¼ 0.001, respect-
ively. **P, 0.01, at post hoc pairwise comparisons.
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idiopathic pericardial effusion, cirrhosis, congestive heart failure, re-
nal failure, or rheumatic disease, chest CT was instrumental for the
final diagnosis by ruling out other possible causes. It should be em-
phasized that patients in our series did not suffer from a mild peri-
carditis and that those with known aetiology were excluded from
the study. Conversely, these patients had all a severe pericardial ef-
fusion or cardiac tamponade of unknown aetiology at presentation,
with no clinical features that allowed an a priori exclusion of cancer
without performing chest CT (Table 1).
In assessing the added value of a workup that includes chest CT in
comparison with two workups including tests recommended by the
European Guidelines for the management of pericardial diseases,
CT proved to be crucial in allowing us to reach a definitive aetio-
logical diagnosis or to provide a strong suspicion which led to fur-
ther appropriate investigations. It must be emphasized that in
staging lung cancer patients, identified by positive cytology in the
pericardial fluid, or in the cases of suspected neoplasia, pneumonia,
and tuberculosis by chest X-ray, CT scan is part of the usual path and
in our series, it allowed us to reach the diagnosis promptly.
All patients with cancer underwent a subsequent abdomen CT
scan for disease staging, as suggested by the current guidelines. It
could be argued about the opportunity to perform early chest
and abdomen CT in one investigation, as this entails only a small in-
crease in the radiation dose and a similar load of contrast media.
Conversely, most of our patients without malignancy did not under-
go an abdomen CT, because the final diagnosis was reached with the
above-mentioned workups and was confirmed at 6-month follow-
up. It therefore remains questionable whether performing early
abdomen CT is useful in all patients with large pericardial effusion.
The aetiological diagnosis in patients presenting with tamponade
or large pericardial effusion as the first manifestation of disease
remains a challenge for the clinicians.6,10 Several pathways have
been proposed in which chest CT is not provided for a first-level
diagnosis or it is regarded as a supplementary test, whether
there is a strong suspicion of pulmonary disease or whether previ-
ous tests are inconclusive.2,6 Our data suggest that in patients
with cardiac tamponade or large pericardial effusion at presentation,
a chest CT should be performed at the beginning of the workup
together with the usual tests, taking into account its significant
diagnostic capacity, non-invasiveness, and the large diffusion of
the technique.
Conclusions
In our series, the prevalence of malignant disease in patients ad-
mitted for large pericardial effusion or cardiac tamponade as
the first manifestation of the disease was high (38%). Clinical
data (fever, dyspnoea, and chest pain) and biochemistry were
not able to differentiate NNpl from Npl patients. Cytological
examination of the pericardial fluid showed high specificity but
low sensitivity in the diagnosis of Npl disease. In all patients
with cardiac tamponade, chest CT was useful either in identifying
the underlying disease or related signs or in excluding other po-
tential causes of pericardial effusion. We conclude that chest
CT is a very useful non-invasive diagnostic tool to identify and
stage pericardial diseases.
Conflict of interest: none declared.
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An unusual cause of early aortic bioprosthetic valve failure
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A 51-year-old woman was diagnosed with critical
aortic stenosis due to a bicuspid aortic valve (AV)
and metastatic lung adenocarcinoma with epider-
mal growth factor receptor (EGFR) mutation at
the same time (Panel A). Two weeks after AV re-
placement with a 21-mm Carpentier-Edwards
Perimount pericardial bioprosthesis (Edwards
Lifesciences, Irvine, CA, USA), she started gefiti-
nib (Iressaw) at 250 mg daily, a selective inhibitor
of the EGFR signal transduction pathway. Al-
though the gefinitib therapy showed a favourable
response, she started having progressive chest
pain and dyspnoea at 6 months after the surgery.
Serial transthoracic echocardiography showed
progressive increases of the maximum and
mean pressure gradients across the bioprosthetic
AV to 75 and 45 mmHg (Panel B). Transoesopha-
geal echocardiography showed nodular thicken-
ing of the leaflets and consequent severe aortic
stenosis and mild aortic regurgitation (Panel C,
D, E and F; see Supplementary data online, Video
S1, S2, S3). Serum inflammatory and rheumatolo-
gic markers were all negative. There was no evi-
dence of bacterial or fungal endocarditis. Because her symptoms were not relieved, a redo AVR was performed using a mechanical
prosthetic valve. The removed bioprosthetic AV revealed multiple nodular lesions and unusual degeneration (Panel G). Histologically,
therewere vegetative dense fibrinous material deposits on the valve and focal acute inflammatory cell infiltrations (Panel H). In the super-
ficial layers of both sides of the valve, there were large numbers of macrophage deposits (Panel I). This case is the first to show a potential
link between EGFR inhibition and AV inflammation and degeneration in humans, although it is highly evident in EGFR-deficient mice.
Supplementary data are available at European Heart Journal – Cardiovascular Imaging online.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2016. For permissions please email: journals.permissions@oup.com.
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